Serum tumour markers are currently used in patients with breast cancer (Bates et al., 1985; von Kleist et al., 1988; Gion, 1992) . Although they provide reliable information on disease progression during follow-up, their real impact on the prognosis of patients is still controversial because of the poor effectiveness of the available treatments for metastatic disease (Zwaveling et al., 1987; Stierer et al., 1989) . The majority of investigators agree on two points: (1) the routine use of tumour markers should be limited to one or two; (2) the first-line tumour marker should be an antigen related to the mucin family (von Kleist et al., 1993) .
CA15.3, MCA and CA549 are three among the most studied tumour markers of the routinely available mucinassociated antigens. CA15.3 is detected by a two-site immunoradiometric assay (Tobias et al., 1985) devised using two monoclonal antibodies: DF3, raised against a membrane fraction of breast cancer tissue, and 115/D8, raised against milk fat globule membrane (Hilkens et al., 1984; Kufe et al., 1984) .
MCA is measured using a two-site enzyme immunoassay method in which a single monoclonal antibody (bl2) raised against the breast cancer cell line ZR-75-1 is used (Stiihli et al., 1985 (Stiihli et al., , 1988 .
Carbohydrate antigen 549 (CA549), identified in 1987, is expressed in a circulating cancer-associated mucin that is recognised by the monoclonal antibody BC4E549, raised against purified membranes from the T417 human breast tumour cells. An immunoradiometric assay was developed by Bray et al. (1987) in which BC4E549 antibody was used as the tracer antibody associated with a second monoclonal antibody raised against milk fat globule membrane (BC4N154) as catcher antibody. Several clinical studies showed its possible clinical usefulness in patients with breast cancer (Bray et al., 1988; Demers et al., 1988; Bhargava et al., 1989; Bagni et al., 1990; Soletormos et al., 1990 Soletormos et al., , 1992 Yerna et al., 1990; Cooper et al., 1992) .
It remains to be determined if there are any more effective members among these mucin-associated antigens. It is worth noting that the majority of the evaluations were carried out categorising the markers as positive or negative. We could demonstrate that significant variations in CA15.3 serum levels may occur when still below the positive/negative threshold level (Gion et al., 1991 (Bombardieri et al., 1989; Gion et al., 1991) .
Statistical analysis Data were evaluated using the Kruskal-Wallis test, the Wilcoxon test, the Fisher exact test, linear regression and Spearman correlation. All computations were carried out using the BMDP statistical software package.
Results

CA549 performance characteristics
Precision Using serum pools, the intra-assay coefficient of variation was lower than 7.0% and the inter-assay CV was lower than 10.0%. These results were confirmed using control material provided by the manufacturer (intra-assay CV lower than 8%, inter-assay CV lower than 11%). The precision profile showed that the kit precision is within 10% in a dose interval ranging from 1O U ml-' to the higher calibration point of the standard curve (73 U ml').
Linearity The dilution results showed a good linearity up to a 1:32 dilution factor with the recovery ranging from 94 to 100%. Analytical sensitivity The lower detectable level of the method was defined as the dose corresponding to the c.p.m. which results from the mean of 20 replicates of standard 'O' plus three standard deviations. It was 0.2 U ml' with the IRMA method and 0.4 U ml-' with the EIA method.
The performance characteristics of the CA549 assay kit were similar to those found by other groups (Cooper et al., 1992 Healthy subjects CA549 in healthy subjects ranged from 1.6 to 20.1 U ml-' (mean 6.7 ± 3.5 s.d. antigen concentration in stage I (median 5.6 U ml', interquartile 4.1-8.4 U ml-) and stage II patients (median 6.2 U ml-', interquartile 4.4-8.4 U ml-') was not significantly different from the control group (Figure 2 ). In patients with breast cancer the antigen level was significantly higher in post-menopausal (median 7.1, interquartile 5.0-10.5 U ml-') than in premenopausal (median 5.0, interquartile 4.0-8.2 U ml-', P <0.0005). No variations in CA549 levels were found in relation to histological type, although a non-significant trend towards higher levels was found in medullary carcinoma, as previously found for MCA and CA15.3 (Bombardieri et al., 1989; Gion et al., 1991) . No association was found between CA549 and both ER and PR when comparing steroid receptors with CA549 as both continuous variables and categorised using several cut-off points (5, 10, 20 and 50 fmolpermg of cytosol protein).
CA549 and tumour burden CA549 was significantly associated with both tumour size and nodal status (Table II) . In the case of tumour size the concentrations of CA549 were significantly different between tumours larger than 5 cm and both those smaller than 2 cm (P = 0.008) and those sized between 2 and 5 cm (P = 0.010). With regard to the number of positive lymph nodes, the antigen concentration was significantly higher in patients with more than three positive lymph nodes than in those with no positive lymph nodes (P<0.001) and in those with 1-3 positive lymph nodes (P <0.001).
The same relation with nodal status was found when considering only patients with more than ten lymph nodes examined, in which axillary status should be considered reliably assessed (data not shown).
As previously shown for MCA and CA15.3 (Bombardieri et al., 1989; Gion et al., 1991) , CA549 failed to distinguish minor differences in tumour extension (i.e. tumours <2 cm vs tumours sized 2-5 cm and/or zero vs 1-3 positive lymph nodes).
Relation between CA549, CA15.3 and MCA A significant linear correlation was found between CA549 and both CA15.3 (Figure 3 Conversely, despite the huge number of tumour marker assays carried out during the follow-up of patients without evidence of disease, their real clinical usefulness is still controversial since the early detection and treatment of metastatic disease does not improve patient survival significantly (Ciatto et al., 1985; Zwaveling et al., 1987; Stierer et al., 1989) . Therefore, it is advisable to restrict the number of tumour markers routinely used until more reliable, dynamic decision criteria are available (von Kleist et al., 1983; Browning et al., 1990; Gion, 1992) . The problem is of relevance in the case of the use of mucin-like associated antigens. In clinical practice the few studies which carried out a comparison between mucin-associated tumour markers reported partly conflicting results (Bombardieri et al., 1989; Barak et al., 1990; Yerna et al., 1990; Bieglmayer et al., 1991; Dnistrian et al., 1991; Miserez et al., 1991; Cazin et al., 1992) . Dnistrian et al. (1991) showed that the combination of CAM26, CAM29 and CA15.3 is more effective in reflecting disease status than individual tests. However, they did not take into account the cost-effectiveness of the strategy they suggest. On the other hand, Cazin et al. (1992) CA549 and CA15.3 are well correlated. However, in a significant number of cases they give discordant information. Longitudinal studies are needed to verify if the association between the two markers may provide a positive cost-effectiveness ratio in the different clinical settings in which these markers are used in breast cancer; 4 The available data do not indicate which of the markers is superior. 5. The three evaluated mucin markers are not interchangeable in individual patients. Therefore, if a patient is monitored with a marker she should be followed up with the same marker. As an alternative, when deciding to change the marker routinely used, the new and the old mucin markers could be assayed side by side for a time, until a new baseline is established with the new marker, before discontinuing the old one.
